

Hypothyroidism

A Review




Layal Chaker, MD, MPH, PhD; Maria Papaleontiou, MD

IMPORTANCE Hypothyroidism is a disease of thyroid hormone deficiency. The prevalence ranges from 0.3% to 12% worldwide, depending on iodine intake, and it is more common in women and older adults. Untreated hypothyroidism can cause serious health complications such as heart failure and myxedema coma.

OBSERVATIONS Hashimoto thyroiditis (an autoimmune disease) is the cause of primary hypothyroidism in up to 85% of patients with hypothyroidism living in areas with adequate nutritional iodine levels. The risk of developing hypothyroidism is associated with genetic factors (having a first-degree relative with hypothyroidism), environmental factors (iodine deficiency), undergoing neck surgery or receiving radiation therapy, pregnancy in the setting of underlying autoimmune thyroid disease, and with the use of certain medications (eg, immune checkpoint inhibitors and amiodarone). Patients with hypothyroidism may have nonspecific symptoms due to metabolic slowing, including fatigue (68%-83%), weight gain (24%-59%), cognitive issues (45%-48%) such as memory loss and difficulty concentrating, and menstrual irregularities (approximately 23%) such as oligomenorrhea and menorrhagia. Hypothyroidism can cause insulin resistance and hyperglycemia in patients with diabetes, increase the risk for cardiovascular events, such as heart failure, and negatively affect female reproductive health, causing disrupted ovulation, infertility, and increased risk of miscarriage. Untreated hypothyroidism may progress to severe hypothyroidism with decompensation (myxedema coma), which is a condition associated with hypothermia, hypotension, and altered mental status that requires treatment in an intensive care unit and has a mortality rate of up to 30%. Hypothyroidism is diagnosed based on biochemical testing; a high thyrotropin (TSH) level and a low free thyroxine (T_4) level indicate overt primary hypothyroidism. Screening for hypothyroidism is not recommended for asymptomatic individuals. Targeted testing is recommended for patients who are considered high risk (eg, patients with type 1 diabetes). First-line treatment for hypothyroidism is synthetic levothyroxine to normalize thyrotropin levels. Initial dosages should be tailored to patient-specific factors. Lower starting doses should be used for older patients or those with atrial fibrillation and coronary artery disease. Thyrotropin monitoring should be performed 6 to 8 weeks after initiating levothyroxine treatment, or when changing the dose, and then annually once the thyrotropin level is at goal to avoid overtreatment or undertreatment, both of which are associated with cardiovascular health risks.

CONCLUSIONS AND RELEVANCE Hypothyroidism may be associated with fatigue, weight gain, memory loss, difficulty concentrating, cardiovascular disease such as heart failure, menstrual irregularities, infertility, and increased risk of miscarriage. Levothyroxine is the first-line treatment to normalize the thyrotropin level and improve clinical manifestations due to hypothyroidism.

JAMA. doi:10.1001/jama.2025.13559
Published online September 3, 2025.

-  [Multimedia](#)
-  [Supplemental content](#)
-  [CME at \[jamacmelookup.com\]\(https://jamacmelookup.com\)](#)

Author Affiliations: Academic Centre for Thyroid Disease, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (Chaker); Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (Chaker); Department of Epidemiology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (Chaker); Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor (Papaleontiou); Institute of Gerontology, University of Michigan, Ann Arbor (Papaleontiou).

Corresponding Author: Maria Papaleontiou, MD, University of Michigan, 2800 Plymouth Rd, Ann Arbor, MI 48109 (mpapaleo@med.umich.edu).

Hypothyroidism is characterized by insufficient production of thyroid hormones. Overt primary hypothyroidism is defined as a thyrotropin (TSH) level greater than the upper limit of the reference range and a free thyroxine (T_4) level less than the lower limit of the reference range. Subclinical hypothyroidism is defined by a thyrotropin level greater than the upper limit of the reference range and a free thyroxine level within the reference range.^{1,2} Hypothyroidism is common, particularly in women and older adults. The prevalence in North America and Europe ranges from 0.3% to 2%,³⁻⁵ but may affect up to 12% of the population, primarily as subclinical hypothyroidism, with higher prevalence in areas with inadequate nutritional iodine levels.^{2,6}

Clinical features vary, but common symptoms include fatigue, weight gain, constipation, dry skin, and cold intolerance.⁷ Untreated hypothyroidism is associated with complications such as cardiovascular disease, impaired cognitive function (including concentration and memory deficits), and, in severe cases, myxedema coma. The first-line treatment is levothyroxine. This treatment is required throughout the patient's life in those with overt hypothyroidism. This Review summarizes current evidence regarding the epidemiology, pathophysiology, clinical presentation, and treatment of primary overt hypothyroidism in nonpregnant adults.

Methods

We searched MEDLINE (including PubMed) and Embase for articles published in the English language from database inception (from 1946 for MEDLINE and from 1974 for Embase) through June 6, 2025 (eMethods in the [Supplement](#)). Overall, 6319 articles were retrieved. We prioritized the inclusion of studies published in the past 5 years but also included older seminal articles. We selected articles based on the quality and rigor of their study designs and methods and their relevance to clinical practice.

A total of 87 studies were included. There were 5 randomized clinical trials; 11 narrative reviews; 9 systematic reviews and/or meta-analyses; 13 retrospective observational studies; 14 prospective observational studies; 10 guidelines, consensus statements, and recommendations; 24 cross-sectional studies (including mendelian randomization studies assessing causality of associations); and 1 case series.

Epidemiology and Risk Factors

Hypothyroidism is classified as primary (defined as inability to produce sufficient thyroid hormone or absence of the thyroid gland), central (defined as secondary due to an underactive pituitary gland or tertiary due to an underactive hypothalamus), or peripheral (extrathyroidal hypothyroidism caused by genetic variants affecting the hormone receptors or the hormone transport or affecting thyroid hormone metabolism). Primary and central hypothyroidism can be acquired or congenital.⁸

More than 99% of cases of hypothyroidism are classified as primary hypothyroidism. Hashimoto thyroiditis (an autoimmune disease) is the cause of primary hypothyroidism in up to 85% of patients with hypothyroidism living in areas with adequate nutritional iodine levels.⁹ Other causes of primary hypothyroidism include io-

dine deficiency, thyroidectomy, thyroiditis (including subacute, postpartum, and silent thyroiditis), radiation therapy, and use of certain medications ([Table 1](#)). Secondary, tertiary, and peripheral hypothyroidism are rare and account for less than 1% of prevalent hypothyroidism cases.

The prevalence of primary hypothyroidism varies depending on the nutritional iodine levels in the region (ie, insufficient, adequate, or excess iodine intake). Iodine, a key nutrient for thyroid hormone synthesis, is a natural element in soil and seawater that can be supplemented in foods (eg, iodized salt). In populations with adequate nutritional iodine levels, such as the UK, the prevalence of spontaneous hypothyroidism (ie, primary hypothyroidism that is not iatrogenic, such as after thyroidectomy) is 1% to 2% of the general population.⁴ The most recent US data (from 1988 to 2012) indicated a prevalence of overt hypothyroidism of 0.3%.¹⁰ The prevalence of undiagnosed overt hypothyroidism in Europe is estimated at 0.65%.⁵ In areas of Asia with inadequate nutritional iodine levels, overt hypothyroidism may affect up to 11% of the population.¹¹

Primary hypothyroidism has a female:male ratio of approximately 5:1.³ Autoimmune hypothyroidism may be present with other autoimmune diseases, such as type 1 diabetes (9.8%) and rheumatoid arthritis (5%-26.2%), reflecting an underlying immune dysregulation and shared genetic factors.¹²⁻¹⁵ Prevalence of hypothyroidism is increased among patients with Down syndrome (31%-65%) and Turner syndrome (12.7%).¹⁶⁻¹⁸ In individuals with a history of infertility or recurrent miscarriages, the prevalence of overt hypothyroidism is approximately 0.2% and the prevalence of subclinical hypothyroidism is 2.4%,¹⁹ which is similar to the general population of women of childbearing age.²⁰ Hypothyroidism is more frequent in Asian and White individuals compared with Black individuals,^{21,22} which may be due to environmental factors (eg, areas with inadequate nutritional iodine levels), genetic factors, or both ([Box](#)).²²⁻²⁵

Hypothyroidism can develop after thyroid surgery or radiation therapy. Approximately 25% to 34% of patients require treatment with levothyroxine after hemithyroidectomy, and up to 42% develop hypothyroidism over a span of 7 years after radiation therapy for head and neck cancer.^{26,27} Drug-induced hypothyroidism is caused by medications such as amiodarone, lithium, and immune checkpoint inhibitors ([Figure 1](#)).^{28,29}

Screening

In 2015, the US Preventive Services Task Force concluded there was insufficient evidence to recommend either screening or no screening for primary hypothyroidism in asymptomatic, nonpregnant adults.³⁰ However, the 2012 guideline³¹ from the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists recommended screening based on serum thyrotropin level for certain high-risk groups, including individuals with autoimmune diseases (such as type 1 diabetes, primary adrenal insufficiency, pernicious anemia, and vitiligo), individuals with a history of thyroid disease in a first-degree relative, and individuals exposed to head and neck radiation. Based on the American Academy of Pediatrics guidelines, individuals with Down syndrome and Turner syndrome should undergo thyrotropin screening annually.^{16,32-34} The 2020 guideline from the American College of

Table 1. Epidemiology and Causes of Hypothyroidism

Types of hypothyroidism	Pathophysiology	Prevalence, % ^a	Age of onset	Risk factors
Primary		0.3-2.0		
Chronic autoimmune thyroiditis (Hashimoto thyroiditis)	Immune-mediated destruction of thyroid cells		Typically 30-50 y	Age, genetic predisposition, environmental triggers (eg, smoking, stress), female sex
Congenital	Reduced thyroid hormone production		Birth	Thyroid agenesis, dysgenesis, or dysmorphogenesis (abnormal thyroid development)
Iatrogenic	Thyroid tissue destruction		Any age	Thyroidectomy, radioactive iodine, radiation
Iodine deficiency	Insufficient thyroid hormone production		Any age	Environmental, dietary
Iodine excess	Inhibition of iodide uptake		Any age	Environmental, dietary
Infiltrative disease (eg, sarcoidosis)	Thyroid tissue destruction		Any age	
Transient				
Postpartum, silent, or subacute thyroiditis	Thyroid gland inflammation (thyroiditis)		Childbearing age	Postpartum
Postprocedural	Iatrogenic		Any age	Inadequate radioactive iodine ablation for Graves disease, subtotal thyroidectomy
Medications			Any age	
Amiodarone or lithium	Inhibition of thyroid hormone synthesis, release, or both			
Interferon alfa or interleukin 2	Immune dysregulation			
Tyrosine kinase inhibitors	Destructive thyroiditis, increased type 3 deiodination			
Immune checkpoint inhibitors	Immune dysregulation by targeting proteins (eg, PD-1, PD-L1, CTLA-4)			
Secondary	Decreased thyrotropin production by the pituitary	<1	Any age	Pituitary disorders (eg, tumor, infiltrative disease, Sheehan syndrome), medications (eg, dopamine, somatostatin), congenital
Tertiary	Decreased thyrotropin-releasing hormone secretion from the hypothalamus	<1	Any age	Disorders damaging the hypothalamus or interfering with blood flow in the hypothalamic-pituitary portal
Peripheral	Aberrant expression of the deiodinase 3 enzyme in tumor tissues (consumptive) Tissue-specific hypothyroidism due to reduced sensitivity to thyroid hormone (resistance to thyroid hormone)	<1	Any age	Genetic predisposition

^a Prevalence is higher in populations with inadequate nutritional iodine levels. Recent epidemiological data were not available to report incidence.

Obstetricians and Gynecologists³⁵ does not recommend universal screening for thyroid disease in all pregnant individuals, but does recommend screening in pregnant individuals who have a personal or family history of thyroid disease, type 1 diabetes, or symptoms suggestive of thyroid disease.

Pathophysiology

The thyroid hormones (thyroxine and triiodothyronine [T_3]) regulate metabolism, growth, and development. Thyroxine and triiodothyronine are produced by the thyroid gland in a 14:1 ratio through the iodination of tyrosine residues on thyroglobulin, which is a process that requires iodine and the thyroid peroxidase enzyme.³⁶ Triiodothyronine and, to a lesser extent, thyroxine modulate gene expression by binding to nuclear receptors in nearly all organ systems and tissues, influencing processes such as energy production, heart rate, and protein synthesis.

More than 99.95% of thyroxine and more than 99.5% of triiodothyronine are transported in the bloodstream while bound to proteins such as thyroxine-binding globulin, transthyretin, albumin, and

lipoproteins. Tissue availability is dependent on the free (ie, unbound) fraction of thyroid hormones.³⁷ Thyroxine, the main hormone produced and released by the thyroid gland, is converted to the active hormone triiodothyronine by deiodinase enzymes in a tissue-specific manner (ie, different types of deiodinase enzymes are expressed in different tissues and are involved in the peripheral conversion of thyroxine to triiodothyronine through deiodination).

Hashimoto thyroiditis is an autoimmune disease characterized by lymphocytic infiltration and autoimmune-mediated thyroid gland destruction, leading to apoptosis of thyroid epithelial cells.^{30,36} Thyroid tissue B cells are activated, leading to the secretion of antithyroid antibodies such as antithyroid peroxidase and antithyroglobulin antibodies, which, coupled with T-cell-mediated and cytokine-mediated apoptosis, result in thyroid gland injury.³⁸

Secondary hypothyroidism is due to reduced secretion of thyrotropin by the pituitary, which leads to decreased thyroid hormone production. Immune checkpoint inhibitors, especially combination therapy involving anti-PD-1, anti-PD-L1, and anti-CTLA-4 drugs, can cause hypophysitis (inflammation of the pituitary gland) that may result in panhypopituitarism.³⁹ In individuals with tertiary hypothyroidism, decreased secretion of thyrotropin-releasing hormone by

Box. Frequently Asked Questions About Hypothyroidism**What are the risk factors for primary hypothyroidism?**

Female sex, genetic predisposition, presence of other autoimmune diseases, and environmental factors (such as iodine intake) are the main risk factors for autoimmune thyroid disease (Hashimoto thyroiditis), which is the most common cause of primary hypothyroidism in the US. Thyroid surgery, pregnancy, radiation therapy, and certain medications (such as amiodarone and immune checkpoint inhibitors) are also associated with an increased risk of primary hypothyroidism.

What is an appropriate initial treatment dose for patients with primary hypothyroidism and how should patients be monitored?

A levothyroxine dose of 1.6 µg/kg/d is considered the full thyroid hormone treatment dose for nonpregnant adults with primary hypothyroidism. However, to avoid overtreatment, lower doses (eg, 25-50 µg/d) are typically prescribed for older adults and patients with cardiovascular disease (eg, atrial fibrillation, coronary artery disease). Thyrotropin levels are typically checked 6 to 8 weeks after initiating therapy or after switching the dose or preparation and annually after the thyrotropin level has normalized. Serum thyrotropin level should also be checked after a change in weight of 4.5 kg or greater, if the patient is experiencing new symptoms of hypothyroidism, or if there is initiation of a medication such as amiodarone that may affect thyroid function.

When should patients with hypothyroidism be referred for consultation with an endocrinologist?

A consultation with an endocrinologist should be considered for patients with hypothyroidism if they (1) are pregnant or planning conception, (2) have a cardiovascular disease (eg, atrial fibrillation, coronary artery disease) or other endocrine disorders (eg, adrenal and pituitary disease, primary or secondary adrenal insufficiency), (3) have medication-induced hypothyroidism, (4) have a history of thyroid cancer, and (5) are being treated with levothyroxine but have difficulty maintaining a euthyroid state.

the hypothalamus reduces thyrotropin secretion. In peripheral hypothyroidism, thyroid hormone production is intact but tissue-specific hypothyroidism occurs due to genetic variants affecting the hormone receptors or the hormone transport, or due to alterations in thyroid hormone metabolism (consumptive hypothyroidism).

Clinical Presentation

Thyroid hormones affect numerous organ systems, including the cardiovascular, musculoskeletal, and nervous systems (Table 2). Patients with hypothyroidism may present with a variety of clinical symptoms and signs^{7,40} that are often related to metabolic slowing due to insufficient thyroid hormone production (Table 2). Common symptoms include fatigue (74%-86%), weight gain (24%-59%), cold intolerance (35%-65%), bradycardia (12%-19%), constipation (33%-41%), and cognitive impairment (45%-48%), including memory loss and difficulty concentrating.^{41,42} Patients aged 70 years or older may have fewer symptoms or signs and are less likely to exhibit some classic signs such as cold intolerance and weight gain compared with younger individuals (aged ≤55 years).⁴¹

The presence of symptoms is more indicative of overt hypothyroidism in men compared with women, with fatigue being the

most common symptom.⁴³ Patients with hypothyroidism and pre-existing comorbidities (such as cardiovascular disease) have reduced health-related quality of life.⁴⁴ In a prospective, population-based cohort study of 147 201 adults in the Netherlands, of the 4537 people receiving thyroid hormone therapy, 70% had a score below the age- and sex-specific cutoff values for the RAND 36-Item Short Form Health Survey (a quality-of-life measure) in the mental health domain of the general health dimension compared with 50% of people not receiving thyroid hormone therapy ($P < .001$).⁴⁴

Hypothyroidism can exacerbate cardiovascular risk factors (such as dyslipidemia) by increasing cholesterol levels, particularly low-density lipoprotein cholesterol, and is associated with diastolic hypertension, increasing the likelihood of cardiovascular disease, particularly in patients with diabetes.^{45,46} For patients with diabetes, untreated or undertreated hypothyroidism can decrease insulin sensitivity and impair glucose disposal (ie, movement of glucose from the bloodstream into cells for energy or storage), making glucose control difficult.⁴⁷

In women, hypothyroidism can cause menstrual irregularities such as oligomenorrhea or menorrhagia (23%),⁴⁸ anovulation, and infertility. The guidelines³¹ from 2012 recommend evaluation of serum thyrotropin level in all women being evaluated for infertility and among those with a history of miscarriage.

In men, hypothyroidism may cause low libido, erectile dysfunction, and reduced sperm motility and may contribute to male hypogonadism.⁴⁹ However, evidence is limited because most studies were performed before 1990 and included small sample sizes. A recent mendelian randomization study supports a causal association between hypothyroidism and decreased sex hormone-binding globulin and testosterone levels.⁵⁰

Signs of severe hypothyroidism may include bradycardia, coarse and dry skin, delayed relaxation of tendon reflexes (particularly in the ankles), loss of lateral eyebrows, and goiter.


Myxedema Coma

If left untreated, severe hypothyroidism can progress to myxedema coma; the estimated incidence rate is 2.56 cases per 1 million US persons per year.⁵¹ Myxedema coma is a life-threatening condition characterized by hypothermia, decreased mental status, hypoventilation, metabolic derangements (hyponatremia, hypoglycemia, lactic acidosis), bradycardia, decreased cardiac contractility, and hypotension. A study analyzing data from the US National Inpatient Sample between 2016 and 2018 reported that 13.4% of 18 635 patients hospitalized for hypothyroidism were diagnosed with myxedema coma, which was associated with a mortality rate of 6.8%.⁵¹ However, an in-hospital mortality rate of up to 30% also has been reported; a difference in the estimates may depend on the definition of myxedema coma, the study design, and the geographic location.⁵²

Assessment and Diagnosis

Hypothyroidism is diagnosed based on serum thyrotropin testing in patients (1) with symptoms such as fatigue, cold intolerance, or dry skin or (2) being evaluated for other conditions such as dyslipidemia,

Figure 1. Medications Affecting Thyroid Function or Interfering With Thyroid Function Testing



^aA dose greater than 160 mg/d inhibits conversion of T₄ to active T₃ via deiodinase type 1 (dose-dependent action).

^bClinicians should be aware of medication interference and adjust the dose of levothyroxine accordingly to achieve a euthyroid status. Medications do not need

to be held or discontinued. High doses of biotin (>5000 µg/d) can interfere with certain thyroid function tests that rely on the biotin × streptavidin interaction and may lead to inaccurate results.

heart failure, or infertility. The diagnosis is more likely among patients with a higher number of symptoms of hypothyroidism. In a US case-control study⁵³ that assessed 17 self-reported hypothyroid symptoms, 76 patients with overt hypothyroidism reported a higher mean percentage of positive hypothyroid symptom responses (30.2%) compared with 147 matched controls (16.5%; $P < .001$). A population-

based, case-control study⁵⁴ reported the hypothyroidism symptom score, which was defined as the number of hypothyroidism-associated symptoms (score range, 0-13), had a good discriminative ability to identify hypothyroidism in younger patients (aged <60 years; area under the receiver operating characteristic curve [AUROC] of 0.91) but not in older patients (aged ≥60 years; AUROC of 0.64).

Table 2. Clinical Presentation of Hypothyroidism^a

Description or organ system	Symptoms and signs (prevalence ^b)	Consequences (prevalence ^b)
Appearance	<ul style="list-style-type: none"> • Dry and coarse skin (55%-70%) • Puffy face • Loss of eyebrows • Hair loss (24%-36%) • Brittle nails 	<ul style="list-style-type: none"> • Periorbital edema • Macroglossia • Generalized edema
Cardiovascular	<ul style="list-style-type: none"> • Shortness of breath on exertion (44%-59%) • Reduced exercise capacity • Bradycardia (12%-19%) 	<ul style="list-style-type: none"> • Endothelial dysfunction • Diastolic hypertension • Hypotension • Dyslipidemia • Hyperhomocysteinemia • Pericardial effusion
Gastrointestinal	<ul style="list-style-type: none"> • Dyspepsia • Bloating • Constipation (33%-41%) 	<ul style="list-style-type: none"> • Esophageal dysmotility • Delayed gastric emptying • Reduced gut motility • Bacterial overgrowth in small intestine • Metabolic dysfunction-associated steatotic liver disease • Ascites (rare)
General metabolic process	<ul style="list-style-type: none"> • Weight gain (24%-59%) • Fatigue and weakness (74%-86%) • Cold intolerance (35%-65%) 	<ul style="list-style-type: none"> • Low metabolic rate • Higher body mass index • Hypothermia • Myxedema coma (<0.0001%)
Hematologic	<ul style="list-style-type: none"> • Fatigue • Paleness 	<ul style="list-style-type: none"> • Hypocoagulable state • Increased risk of bleeding • Anemia
Musculoskeletal	<ul style="list-style-type: none"> • Muscle weakness and cramps • Joint pain • Delayed relaxation of tendon reflexes (75%) 	<ul style="list-style-type: none"> • Myopathy (30%-80%)
Neurological or psychological	<ul style="list-style-type: none"> • Paresthesias • Cognitive impairment (45%-48%) (eg, slowed mentation, slowed speech, short-term memory impairment) • Depression 	<ul style="list-style-type: none"> • Carpal tunnel syndrome • Peripheral neuropathy • Cognitive impairment • Encephalopathy (rare)
Neurosensory	<ul style="list-style-type: none"> • Hearing loss • Tinnitus • Voice hoarseness 	<ul style="list-style-type: none"> • Conductive and sensorineural hearing impairment • Dysphonia
Reproductive	<ul style="list-style-type: none"> • Irregular menstrual cycles (23%) • Decreased libido • Galactorrhea • Erectile dysfunction 	<ul style="list-style-type: none"> • Sexual dysfunction • Infertility • Hyperprolactinemia • Pituitary hyperplasia (rare)
Respiratory	<ul style="list-style-type: none"> • Shortness of breath on exertion (44%-59%) • Reduced exercise capacity 	<ul style="list-style-type: none"> • Sleep apnea • Pleural effusions

^a Clinical manifestations are highly variable depending on the age of onset and the duration and severity of hypothyroidism.

^b Recent epidemiological data were not available to report incidence.

Diagnostic assessment for hypothyroidism is based on serum thyrotropin level, and, if abnormal, serum free thyroxine (free T₄) level (Figure 2). Serum thyrotropin is recommended as the initial diagnostic test because it is the most reliable indicator of thyroid status in outpatients without clinically suspected pituitary or hypothalamic disease who are not taking medications that affect thyrotropin secretion, such as glucocorticoids or lithium. Serum thyrotropin sensitivity is approximately 98% and specificity is 92% for identifying overt thyroid dysfunction.³⁰ Clinicians should suspect pituitary or hypothalamic disease in patients with hypothyroid symptoms and other signs of pituitary or hypothalamic dysfunction, such as adrenal insufficiency, low libido, or menstrual irregularities. If thyrotropin level is high, free thyroxine should be measured or repeat thyrotropin testing should be performed. There is no role for triiodothyronine testing in the diagnosis of hypothyroidism.

Measuring thyroid peroxidase or antithyroglobulin antibodies is not recommended for the diagnosis of primary hypothyroidism because the prevalence of thyroid antibody test positivity ranges from 5% to 20% in individuals without hypothyroidism.^{55,56} For patients with hypothyroidism, use of ultrasonography in the absence


of goiter or thyroid nodules is not recommended by endocrine societies.⁵⁷

Treatment

The first-line thyroid hormone treatment for patients with hypothyroidism is synthetic levothyroxine.¹ Levothyroxine is administered orally and should be taken on an empty stomach 30 to 60 minutes before breakfast with water; taking levothyroxine in the evening at least 2 hours after eating food is also acceptable.⁵⁸ For patients who are fasting (eg, during Ramadan), levothyroxine can be taken at bedtime with a minimum 2-hour interval since the last meal.⁵⁹⁻⁶¹ Patients should be instructed to avoid taking levothyroxine within 4 hours of ingesting calcium or iron supplements or other medications that can interfere with absorption (such as proton pump inhibitors and phosphate binders).

The full adult thyroid hormone replacement dosage with levothyroxine is 1.6 µg/kg/d of actual body weight, but the initial dose should be individualized. Lower doses should be prescribed for older

Figure 2. Assessment of Hypothyroidism and the Therapeutic Approach to the Management of Hypothyroidism in Nonpregnant Adults



patients and for those with specific comorbidities (Figure 2). Higher doses should be prescribed during pregnancy. Oral levothyroxine is available as a tablet, gel capsule, or liquid. The 2012 ATA guidelines³¹ recommended an initial levothyroxine dose of 25 µg/d to 50 µg/d for patients with cardiovascular disease. Levothyroxine-treated women of childbearing age should be informed that dose requirements increase during pregnancy. For patients with hypothyroidism, the 2017 ATA pregnancy guidelines⁶² recommend increasing the levothyroxine dose by 30% (1 extra pill twice per week) once the pregnancy is confirmed and then continue with the increased dose until delivery; serum thyrotropin level should be measured approximately every 4 weeks until midgestation and at least once near 30 weeks' gestation.

It is unclear if repeat thyrotropin testing should be performed after switching levothyroxine preparations. The 2014 ATA guidelines¹ for the treatment of hypothyroidism advised avoiding switches between levothyroxine products because of potential variations in the administered dose (weak recommendation based on low-quality evidence). A cohort study⁶³ of levothyroxine brand switching using 2 Dutch registries with 59 787 patients taking levothyroxine reported that in patients maintaining a euthyroid state, switching to a different brand at an equivalent dose led to biochemical signs of overreplacement (reflected as a thyrotropin level

below the reference range) in up to 63% of cases. However, in 2 comparative effectiveness studies,^{64,65} switching was not associated with clinically significant changes in thyrotropin level; one of the studies included a comparison of generic vs brand-name levothyroxine among 17 598 US adults and the other study included switching among different generic levothyroxine products in 15 829 US adults.

For primary hypothyroidism, regular thyrotropin monitoring after dose adjustments is important to ensure optimal treatment. Thyrotropin levels are typically checked 6 to 8 weeks after initiating therapy, or after switching the dose or preparation, and annually after the thyrotropin level has normalized. Serum thyrotropin level should also be checked after a change in weight of 4.5 kg or greater, if the patient is experiencing new symptoms of hypothyroidism, or if there is initiation of a medication such as amiodarone that may affect thyroid function. Treatment targets include normalization of thyrotropin, improvement in clinical manifestations of hypothyroidism, and avoidance of adverse events such as atrial fibrillation and heart failure due to over- or undertreatment.¹ For patients with central hypothyroidism, free thyroxine level should be checked to monitor the adequacy of the levothyroxine dose; the target level of free thyroxine should be in the upper half of the reference range.³¹

Overtreatment and Undertreatment

Overtreatment with levothyroxine, characterized by thyrotropin levels below the lower limit of the reference range (typically serum thyrotropin level <0.5 mIU/L), and undertreatment, characterized by thyrotropin levels above the upper limit of the reference range, may occur. A population-based retrospective study⁶⁶ reported that one-third of women with hypothyroidism ($n = 6141$) in Spain had a measured thyrotropin level higher than (ie, overtreated) or lower than the reference range (ie, undertreated) 1 year before pregnancy. Among patients with hypothyroidism taking levothyroxine, studies⁶⁷⁻⁷⁰ have reported a cumulative incidence of low thyrotropin levels in 5% to 41% and high thyrotropin levels in approximately 5% to 21%, with varying incidence depending on the population, clinical setting, and criteria used to define abnormal thyrotropin levels. In a recent retrospective cohort study⁷¹ that included 20 724 older primary care patients taking levothyroxine, 34% had thyrotropin levels below the reference range, which was more frequent in women than in men (36.7% vs 23.9%, respectively). In addition, 25% of patients had a thyrotropin level that was 10 mIU/L or greater at least once, which was more common among men than women (23.8% vs 28.7%, respectively).⁷¹

Serum thyrotropin levels below or above the reference range while taking levothyroxine have been associated with increased risk of adverse cardiovascular events.⁷²⁻⁷⁵ In a retrospective cohort study⁷⁵ including 705 307 US veterans who received thyroid hormone treatment, 10.8% died of cardiovascular causes over a median follow-up of 4 years. After adjusting for age, sex, traditional cardiovascular risk factors (including hypertension, smoking, and previous cardiovascular disease or arrhythmia), and when analyzing thyrotropin and free thyroxine levels as time-varying covariates, the patients with thyrotropin levels less than 0.1 mIU/L had an increased risk of cardiovascular mortality (adjusted hazard ratio [HR], 1.39 [95% CI, 1.32-1.47]) as did the patients with free thyroxine levels greater than 1.9 ng/dL (adjusted HR, 1.29 [95% CI, 1.20-1.40]) compared with patients maintaining a euthyroid state.⁷⁵ Patients with thyrotropin levels greater than 20 mIU/L (adjusted HR, 2.67 [95% CI, 2.55-2.80]) and free thyroxine levels less than 0.7 ng/dL (adjusted HR, 1.56 [95% CI, 1.50-1.63]) had an increased risk of cardiovascular mortality compared with patients maintaining a euthyroid state.⁷⁵

In another retrospective cohort study⁷⁴ including 733 208 US veterans receiving thyroid hormone treatment, 11.1% developed atrial fibrillation and 6.3% had a stroke over a median follow-up of 59 months. Thyrotropin levels less than 0.1 mIU/L (adjusted odds ratio [OR], 1.33 [95% CI, 1.24-1.43]) and free thyroxine levels greater than 1.9 ng/dL (adjusted OR, 1.17 [95% CI, 1.06-1.30]) were associated with an increased incidence of stroke compared with levels in the euthyroid range, even after adjusting for several covariates including age, sex, smoking, and prior history of atrial fibrillation. In addition, thyrotropin levels greater than 5.5 mIU/L (adjusted OR, 1.29 [95% CI, 1.26-1.33]) and free thyroxine levels less than 0.7 ng/dL (adjusted OR, 1.29 [95% CI, 1.22-1.35]) were associated with increased incidence of stroke compared with levels in the euthyroid range.

In a population-based study,⁷³ patients receiving long-term thyroid hormone treatment with levothyroxine ($N = 17\,684$) had an in-

creased incidence of fractures when either overtreated (4.3% in overtreated patients vs 2.6% in patients in euthyroid range; adjusted OR, 2.02 [95% CI, 1.55-2.62]) or undertreated (3.8% in undertreated patients vs 2.6% in patients in the euthyroid range; adjusted OR, 1.83 [95% CI, 1.41-2.37]). Patients with thyrotoxicosis, including due to overtreatment with thyroid hormone therapy, had an increased incidence of cognitive disorders compared with those without thyrotoxicosis (11% v 6.4%, respectively) ($N = 65\,931$; adjusted HR, 1.34 [95% CI, 1.10-1.63]).⁷⁶ Recent studies^{68,77} have suggested that 18% to 30% of patients receiving thyroid hormone treatment with levothyroxine had normal thyrotropin concentrations prior to initiation of the medication; this practice can lead to overtreatment and patient harm.

Treatment of Myxedema Coma

The first-line therapy for myxedema coma is empiric glucocorticoids followed by administration of intravenous levothyroxine. Empiric glucocorticoids are given to treat possible concomitant adrenal insufficiency (100 mg of hydrocortisone administered intravenously every 8 hours initially, with subsequent tapering and discontinuation after adrenal insufficiency is ruled out).¹ Concomitant intravenous liothyronine (a synthetic form of triiodothyronine) may be given, if available, because thyroxine conversion to triiodothyronine may be decreased. Patients with myxedema coma should be closely monitored for arrhythmias and cardiac ischemia and receive supportive care and treatment of hypothermia, respiratory failure, and electrolyte imbalances. Early diagnosis and management of myxedema coma in an intensive care unit setting are important to improve survival. Clinical and biochemical improvements typically occur within 1 week with prompt intravenous administration of thyroid hormone treatment, and then patients can be switched to oral medications.

Practical Considerations

Patients taking levothyroxine may not achieve target thyrotropin levels due to several factors, including low initial levothyroxine dosing, dose adjustments not made based on thyrotropin levels, medication nonadherence, and not taking the medication consistently on an empty stomach, which can reduce its absorption.

Gastrointestinal conditions, such as celiac disease or *Helicobacter pylori* infection, can impair levothyroxine absorption, leading to higher than anticipated dose requirements. Liquid and softgel formulations are better absorbed and may be helpful in patients with diagnosed malabsorption.⁷⁸ A systematic review of 13 studies (5 randomized clinical trials, 7 prospective nonrandomized studies, and 1 cross-sectional study) that included 1697 patients reported that liquid and softgel levothyroxine formulations had the same amount of absorption (based on patients' serum thyrotropin levels) whether taken at breakfast, with other meals, or with other drugs.⁷⁹ Chronic kidney disease and cirrhosis can affect thyroid hormone metabolism and excretion, leading to lower levothyroxine dose requirements.^{80,81}

Alternative thyroid hormone preparations to levothyroxine include liothyronine and desiccated thyroid extract, which is derived

from the thyroid glands of pigs and contains both thyroxine and triiodothyronine. Current guidelines^{1,82} do not recommend routine use of desiccated thyroid extract or combination therapy with synthetic triiodothyronine and thyroxine. In view of conflicting evidence⁸³⁻⁸⁵ regarding the use of vitamin D and selenium as adjunctive treatment for hypothyroidism, current guidelines^{1,31} do not recommend vitamin D or selenium for the treatment of hypothyroidism.

Both iodine deficiency and excessive iodine intake can induce hypothyroidism, particularly in patients with underlying autoimmune thyroid disease. The World Health Organization and the ATA recommend an intake of 150 µg/d of iodine in adults and adolescents, with a higher intake of 250 µg/d during pregnancy and lactation. Recommended levels of iodine intake are generally obtained through diet in nonpregnant individuals living in areas with adequate nutritional iodine levels and also can be achieved by taking prenatal vitamins during pregnancy and lactation.⁸⁶

Either discontinuation or dose reduction (deprescribing) of levothyroxine should be considered for patients maintaining a euthyroid state and who were started on the medication for nonspecific symptoms, and for those with low serum thyrotropin while taking levothyroxine. Low-quality evidence suggests that up to 11.8% of patients with a prior diagnosis of overt hypothyroidism continue to maintain a euthyroid state for up to a median follow-up of 60 months after discontinuation of levothyroxine.⁸⁷ Deprescribing involves gradually tapering the dose, typically by 25 µg every 6 to 8 weeks,

while monitoring symptoms and testing thyroid function every 6 to 8 weeks.

An endocrinologist should be consulted for individuals with hypothyroidism who are pregnant or trying to conceive; patients with cardiovascular, pituitary, or adrenal disease; patients with medication-induced hypothyroidism; patients with a history of thyroid cancer; and patients with frequent fluctuations on their thyroid function test results (ie, for thyrotropin and free thyroxine) or when the test results are difficult to interpret (Box).

Limitations

This review has limitations. First, this was not a systematic review and some relevant articles were probably omitted. Second, a formal quality assessment of the literature was not conducted. Third, high-quality data are lacking for some treatment outcomes.

Conclusions

Hypothyroidism may be associated with fatigue, weight gain, memory loss, difficulty concentrating, cardiovascular disease such as heart failure, menstrual irregularities, infertility, and increased risk of miscarriage. Levothyroxine is the first-line treatment to normalize the thyrotropin level and improve clinical manifestations due to hypothyroidism.

ARTICLE INFORMATION

Accepted for Publication: July 17, 2025.

Published Online: September 3, 2025.
doi:10.1001/jama.2025.13559

Conflict of Interest Disclosures: Dr Chaker reported receiving grant support from ZonMW (Netherlands Organization for Health Research and Development) and receiving nonfinancial support from Abbott Diabetes Care. Dr Papaleontiou reported receiving grant support from the National Institute on Aging.

Additional Contributions: We acknowledge Wichor Bramer, PhD (librarian at Erasmus Medical Center Rotterdam), for his help with the literature searches. Dr Bramer was not compensated for his contributions.

Submissions: We encourage authors to submit papers for consideration as a Review. Please contact Kristin Walter, MD, at kristin.walter@jamanetwork.org.

REFERENCES

1. Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. *Thyroid*. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028
2. Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. *JAMA*. 2019;322(2):153-160. doi:10.1001/jama.2019.9052
3. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. *J Clin Endocrinol Metab*. 2014;99(3):923-931. doi:10.1210/jc.2013-2409

4. Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. *Thyroid*. 2002;12(10):839-847. doi:10.1089/105072502761016458
5. Mendes D, Alves C, Silverio N, Batel Marques F. Prevalence of undiagnosed hypothyroidism in Europe: a systematic review and meta-analysis. *Eur Thyroid J*. 2019;8(3):130-143. doi:10.1159/000499751
6. Li Y, Teng D, Ba J, et al. Efficacy and safety of long-term universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China. *Thyroid*. 2020;30(4):568-579. doi:10.1089/thy.2019.0067
7. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case-control study. *Eur J Endocrinol*. 2014;171(5):593-602. doi:10.1530/EJE-14-0481
8. Garrelfs MR, Mooij CF, Boelen A, van Trotsenburg ASP, Zwaveling-Soonawala N. Newborn screening for central congenital hypothyroidism: past, present and future. *Eur Thyroid J*. 2025;14(1):e240329. doi:10.1530/ETJ-24-0329
9. Carlé A, Laurberg P, Pedersen IB, et al. Epidemiology of subtypes of hypothyroidism in Denmark. *Eur J Endocrinol*. 2006;154(1):21-28. doi:10.1530/eje.1.02068
10. Zhang X, Wang Y, Wang H, Zhang X. Trends in prevalence of thyroid dysfunction and its associations with mortality among US participants, 1988-2012. *J Clin Endocrinol Metab*. 2024;109(2):e657-e666. doi:10.1210/clinem/dgad558
11. Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari N. Prevalence of hypothyroidism in adults: an epidemiological study in eight cities of

India. *Indian J Endocrinol Metab*. 2013;17(4):647-652. doi:10.4103/2230-8210.113755

12. Zheng S, Liu L, Liang K, et al. Multi-omics insight into the metabolic and cellular characteristics in the pathogenesis of hypothyroidism. *Commun Biol*. 2024;7(1):990. doi:10.1038/s42003-024-06680-x
13. Nederstigt C, Uitbeijerse BS, Janssen LGM, Corssmit EPM, de Koning EJP, Dekkers OM. Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis. *Eur J Endocrinol*. 2019;180(2):135-144. doi:10.1530/EJE-18-0515
14. Liu YJ, Miao HB, Lin S, Chen Z. Association between rheumatoid arthritis and thyroid dysfunction: a meta-analysis and systematic review. *Front Endocrinol (Lausanne)*. 2022;13:1015516. doi:10.3389/fendo.2022.1015516
15. Liu R, Shang X, Fu Y, Wang Y, Wang P, Yan S. Shared genetic architecture between hypothyroidism and rheumatoid arthritis: a large-scale cross-trait analysis. *Mol Immunol*. 2024;168:17-24. doi:10.1016/j.molimm.2024.02.002
16. Lavigne J, Sharr C, Elsharkawi I, et al. Thyroid dysfunction in patients with Down syndrome: results from a multi-institutional registry study. *Am J Med Genet A*. 2017;173(6):1539-1545. doi:10.1002/ajmg.a.38219
17. Wood JC, Gochyyev P, Santoro SL. Adherence to adult clinical practice guidelines for Down syndrome. *Am J Med Genet A*. 2025;197(1):e63850. doi:10.1002/ajmg.a.63850
18. Mohamed SOO, Elkhidir IHE, Abuzied AIH, Nouredin AAMH, Ibrahim GAA, Mahmoud AAA. Prevalence of autoimmune thyroid diseases among the Turner syndrome patients: meta-analysis of cross sectional studies. *BMC Res Notes*. 2018;11(1):842. doi:10.1186/s13104-018-3950-0

19. Dhillon-Smith RK, Tobias A, Smith PP, et al. The prevalence of thyroid dysfunction and autoimmunity in women with history of miscarriage or subfertility. *J Clin Endocrinol Metab*. 2020;105(8):dgaa302. doi:10.1210/clinem/dgaa302
20. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH and total T₄ in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). *Thyroid*. 2007;17(12):1211-1223. doi:10.1089/thy.2006.0235
21. Wyne KL, Nair L, Schneiderman CP, et al. Hypothyroidism prevalence in the United States: a retrospective study combining National Health and Nutrition Examination Survey and claims data, 2009-2019. *J Endocr Soc*. 2022;7(1):bvac172. doi:10.1210/endo/bvac172
22. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. *JAMA*. 2014;311(15):1563-1565. doi:10.1001/jama.2013.285606
23. Petit P, Chamot S, Al-Salameh A, Cancé C, Desaillood R, Bonnetterre V. Farming activity and risk of treated thyroid disorders: insights from the TRACTOR project, a nationwide cohort study. *Environ Res*. 2024;249:118458. doi:10.1016/j.envres.2024.118458
24. Sterenborg RBTM, Steinbrenner I, Li Y, et al; GHS DiscovEHR; Regeneron Genetics Center. Multi-trait analysis characterizes the genetics of thyroid function and identifies causal associations with clinical implications. *Nat Commun*. 2024;15(1):888. doi:10.1038/s41467-024-44701-9
25. Chaker L, Korevaar TI, Medici M, et al. Thyroid function characteristics and determinants: the Rotterdam study. *Thyroid*. 2016;26(9):1195-1204. doi:10.1089/thy.2016.0133
26. Chow JCH, Lui JCF, Cheung KM, et al. Post-radiation primary hypothyroidism in patients with head and neck cancer: external validation of thyroid gland dose-volume constraints with long-term endocrine outcomes. *Radiother Oncol*. 2022;177:105-110. doi:10.1016/j.radonc.2022.10.034
27. Li Z, Qiu Y, Fei Y, Xing Z, Zhu J, Su A. Prevalence of and risk factors for hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis. *Endocrine*. 2020;70(2):243-255. doi:10.1007/s12020-020-02410-5
28. Burch HB. Drug effects on the thyroid. *N Engl J Med*. 2019;381(8):749-761. doi:10.1056/NEJMr1901214
29. Zhou X, Iwama S, Kobayashi T, Ando M, Arima H. Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. *J Clin Endocrinol Metab*. 2023;108(10):e1056-e1062. doi:10.1210/clinem/dgad231
30. LeFevre ML; US Preventive Services Task Force. Screening for thyroid dysfunction: US Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2015;162(9):641-650. doi:10.7326/M15-0483
31. Garber JR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Endocr Pract*. 2012;18(6):988-1028. doi:10.4158/EPI12280.GL
32. Naessén S, Eliasson M, Berntorp K, et al. Autoimmune disease in Turner syndrome in Sweden: an up to 25 years' controlled follow-up study. *J Clin Endocrinol Metab*. 2024;109(2):e602-e612. doi:10.1210/clinem/dgad566
33. Bull MJ, Trotter T, Santoro SL, et al; Council on Genetics. Health supervision for children and adolescents with Down syndrome. *Pediatrics*. 2022;149(5):e2022057010. doi:10.1542/peds.2022-057010
34. Gravholt CH, Andersen NH, Christin-Maitre S, et al; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome. *Eur J Endocrinol*. 2024;190(6):G53-G151. doi:10.1093/ajendo/lvae050
35. American College of Obstetricians and Gynecologists. Thyroid disease in pregnancy: ACOG practice bulletin number 223. *Obstet Gynecol*. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893
36. Chiovato L, Bassi P, Santini F, et al. Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. *J Clin Endocrinol Metab*. 1993;77(6):1700-1705.
37. Peeters RP, Visser TJ. Metabolism of thyroid hormone. In: Feingold KR, Ahmed SF, Anawalt B, et al, eds. *Endotext*. MD Text.com Inc; 2000. Accessed August 25, 2025. <https://www.ncbi.nlm.nih.gov/books/NBK285545/>
38. Weetman AP. An update on the pathogenesis of Hashimoto's thyroiditis. *J Endocrinol Invest*. 2021;44(5):883-890. doi:10.1007/s40618-020-01477-1
39. Byun DJ, Wolchok JD, Rosenberg LM, Giotra M. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies. *Nat Rev Endocrinol*. 2017;13(4):195-207. doi:10.1038/nrendo.2016.205
40. Carlé A, Karmisholt JS, Knudsen N, et al. Does subclinical hypothyroidism add any symptoms? evidence from a Danish population-based study. *Am J Med*. 2021;134(9):1115-1126.e1. doi:10.1016/j.amjmed.2021.03.009
41. Doucet J, Triviale C, Chassagne P, et al. Does age play a role in clinical presentation of hypothyroidism? *J Am Geriatr Soc*. 1994;42(9):984-986. doi:10.1111/j.1532-5415.1994.tb06592.x
42. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med*. 2000;160(4):526-534. doi:10.1001/archinte.160.4.526
43. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. Gender differences in symptoms of hypothyroidism: a population-based DanThyr study. *Clin Endocrinol (Oxf)*. 2015;83(5):717-725. doi:10.1111/cen.12787
44. Wouters HJCM, Wolffenbuttel BHR, Muller Kobold AC, Links TP, Huls G, van der Klauw MM. Hypothyroidism, comorbidity and health-related quality of life: a population-based study. *Endocr Connect*. 2023;12(12):e230266. doi:10.1530/EC-23-0266
45. Chen HS, Wu TE, Jap TS, et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in type 2 diabetic patients. *Diabet Med*. 2007;24(12):1336-1344. doi:10.1111/j.1464-5491.2007.02270.x
46. Penna GC, Bensensor IM, Bianco AC, Ettleson MD. Thyroid hormone homeostasis in levothyroxine-treated patients: findings from ELSA-Brasil. *J Clin Endocrinol Metab*. 2024;109(10):2504-2512. doi:10.1210/clinem/dgae139
47. Kim MK, Kwon HS, Baek KH, et al. Effects of thyroid hormone on A1C and glycated albumin levels in nondiabetic subjects with overt hypothyroidism. *Diabetes Care*. 2010;33(12):2546-2548. doi:10.2337/dc10-0988
48. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. *Clin Endocrinol (Oxf)*. 1999;50(5):655-659. doi:10.1046/j.1365-2265.1999.00719.x
49. La Vignera S, Vita R, Condorelli RA, et al. Impact of thyroid disease on testicular function. *Endocrine*. 2017;58(3):397-407. doi:10.1007/s12020-017-1303-8
50. Kjaergaard AD, Marouli E, Papadopoulou A, et al. Thyroid function, sex hormones and sexual function: a Mendelian randomization study. *Eur J Epidemiol*. 2021;36(3):335-344. doi:10.1007/s10654-021-00721-z
51. Chen DH, Hurtado CR, Chang P, Zakher M, Angell TE. Clinical features and outcomes of myxedema coma in patients hospitalized for hypothyroidism: analysis of the United States National Inpatient Sample. *Thyroid*. 2024;34(4):419-428. doi:10.1089/thy.2023.0559
52. Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Clinical characteristics and outcomes of myxedema coma: analysis of a national inpatient database in Japan. *J Epidemiol*. 2017;27(3):117-122. doi:10.1016/j.je.2016.04.002
53. Canaris GJ, Steiner JF, Ridgway EC. Do traditional symptoms of hypothyroidism correlate with biochemical disease? *J Gen Intern Med*. 1997;12(9):544-550. doi:10.1046/j.1525-1497.1997.07109.x
54. Carlé A, Pedersen IB, Knudsen N, et al. Hypothyroid symptoms fail to predict thyroid insufficiency in old people: a population-based case-control study. *Am J Med*. 2016;129(10):1082-1092. doi:10.1016/j.amjmed.2016.06.013
55. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*. 2002;87(2):489-499. doi:10.1210/jcem.87.2.8182
56. Pedersen IB, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Laurberg P. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. *Clin Endocrinol (Oxf)*. 2003;58(1):36-42. doi:10.1046/j.1365-2265.2003.01633.x
57. Peterson AS. Choosing Wisely XXXIX and top tips. *J Lancaster Gen Hosp*. 2022;17(3):93-96. <https://www.jlgh.org>
58. Jonklaas J. Optimal thyroid hormone replacement. *Endocr Rev*. 2022;43(2):366-404. doi:10.1210/endo/bnab031
59. Al-Qahtani KM, Aldeeri IA, Alshaibi AM, et al. Optimal timing of thyroid hormone replacement during Ramadan fasting: a randomized controlled trial in patients with prior total thyroidectomy.

- Thyroid*. 2022;32(9):1029-1036. doi:10.1089/thy.2022.0110
60. Belal MM, Youssef AR, Baker H, et al. Effect of Ramadan fasting on thyroid functions in hypothyroid patients taking levothyroxine: a systematic review and meta-analysis. *Ir J Med Sci*. 2024;193(2):741-753. doi:10.1007/s11845-023-03526-z
 61. Alzahrani AS, Mukhtar N, Alhammad Z, et al. A randomized clinical trial comparing 2 levothyroxine regimens during Ramadan fasting in thyroidectomized patients. *J Endocr Soc*. 2024;8(11):bvae173. doi:10.1210/jendso/bvae173
 62. Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid*. 2017;27(3):315-389. doi:10.1089/thy.2016.0457
 63. Flinterman LE, Kuiper JG, Korevaar JC, et al. Impact of a forced dose-equivalent levothyroxine brand switch on plasma thyrotropin: a cohort study. *Thyroid*. 2020;30(6):821-828. doi:10.1089/thy.2019.0414
 64. Brito JP, Ross JS, Sangaralingham L, et al. Comparative effectiveness of generic vs brand-name levothyroxine in achieving normal thyrotropin levels. *JAMA Netw Open*. 2020;3(9):e2017645. doi:10.1001/jamanetworkopen.2020.17645
 65. Brito JP, Deng Y, Ross JS, et al. Association between generic-to-generic levothyroxine switching and thyrotropin levels among US adults. *JAMA Intern Med*. 2022;182(4):418-425. doi:10.1001/jamainternmed.2022.0045
 66. Tena Vivó G, Parellada Esquius N, Cunillera Puértolas O, Albareda Riera M, Isidro Albaladejo M, Vila Ballester L. Description of thyroid disorders the year before conception: a population-based study. *Front Endocrinol (Lausanne)*. 2023;14:1236505. doi:10.3389/fendo.2023.1236505
 67. Mammen JS, McGready J, Oxman R, Chia CW, Ladenson PW, Simonsick EM. Thyroid hormone therapy and risk of thyrotoxicosis in community-resident older adults: findings from the Baltimore Longitudinal Study of Aging. *Thyroid*. 2015;25(9):979-986. doi:10.1089/thy.2015.0180
 68. la Cour JL, Medici BR, Grand MK, et al. Risk of over- and under- treatment with levothyroxine in primary care in Copenhagen, Denmark. *Eur J Endocrinol*. 2021;185(5):673-679. doi:10.1530/EJE-21-0485
 69. Somwaru LL, Arnold AM, Joshi N, Fried LP, Cappola AR. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. *J Clin Endocrinol Metab*. 2009;94(4):1342-1345. doi:10.1210/jc.2008-1696
 70. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. *Br J Gen Pract*. 1993;43(368):107-109.
 71. Adams R, Mammen JS. Sex differences in risk for iatrogenic thyrotoxicosis among older adults: an analysis from real-world clinical data. *Thyroid*. 2025;35(5):485-493. doi:10.1089/thy.2024.0604
 72. Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. *Eur J Endocrinol*. 2019;180(6):407-416. doi:10.1530/EJE-19-0006
 73. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. *J Clin Endocrinol Metab*. 2010;95(1):186-193. doi:10.1210/jc.2009-1625
 74. Papaleontiou M, Levine DA, Reyes-Gastelum D, Hawley ST, Banerjee M, Haymart MR. Thyroid hormone therapy and incident stroke. *J Clin Endocrinol Metab*. 2021;106(10):e3890-e3900. doi:10.1210/clinem/dgab444
 75. Evron JM, Hummel SL, Reyes-Gastelum D, Haymart MR, Banerjee M, Papaleontiou M. Association of thyroid hormone treatment intensity with cardiovascular mortality among US veterans. *JAMA Netw Open*. 2022;5(5):e2211863. doi:10.1001/jamanetworkopen.2022.11863
 76. Adams R, Oh ES, Yasar S, Lyketsos CG, Mammen JS. Endogenous and exogenous thyrotoxicosis and risk of incident cognitive disorders in older adults. *JAMA Intern Med*. 2023;183(12):1324-1331. doi:10.1001/jamainternmed.2023.5619
 77. Brito JP, Ross JS, El Kawkgi OM, et al. Levothyroxine use in the United States, 2008-2018. *JAMA Intern Med*. 2021;181(10):1402-1405. doi:10.1001/jamainternmed.2021.2686
 78. Liu H, Li W, Zhang W, Sun S, Chen C. Levothyroxine: conventional and novel drug delivery formulations. *Endocr Rev*. 2023;44(3):393-416. doi:10.1210/edrv/bnac030
 79. Oteri V, Volpe S, Lopes M, et al. Therapeutic efficacy and patient compliance of levothyroxine liquid and softgel formulations taken with meals: a systematic review. *Endocrine*. 2025;87(1):48-58. doi:10.1007/s12020-024-04016-7
 80. Benvenega S, Capodicasa G, Perelli S, Ferrari SM, Fallahi P, Antonelli A. Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis. *Front Endocrinol (Lausanne)*. 2018;9:150. doi:10.3389/fendo.2018.00150
 81. Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. *Curr Opin Endocrinol Diabetes Obes*. 2016;23(5):407-415. doi:10.1097/MED.0000000000000275
 82. Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. *Eur Thyroid J*. 2021;10(1):10-38. doi:10.1159/000512970
 83. Waterhouse M, Pham H, Rahman ST, et al. The effect of vitamin D supplementation on hypothyroidism in the randomized controlled D-Health trial. *Thyroid*. 2023;33(11):1302-1310. doi:10.1089/thy.2023.0317
 84. Safari S, Rafraf M, Malekian M, Molani-Gol R, Asghari-Jafarabadi M, Mobasser M. Effects of vitamin D supplementation on metabolic parameters, serum irisin and obesity values in women with subclinical hypothyroidism: a double-blind randomized controlled trial. *Front Endocrinol (Lausanne)*. 2023;14:1306470. doi:10.3389/fendo.2023.1306470
 85. Larsen C, Winther KH, Cramon PK, et al. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. *Eur Thyroid J*. 2024;13(1):e230175.
 86. Leung AM, Avram AM, Brenner AV, et al. Potential risks of excess iodine ingestion and exposure: statement by the American Thyroid Association public health committee. *Thyroid*. 2015;25(2):145-146. doi:10.1089/thy.2014.0331
 87. Burgos N, Toloza FJK, Singh Ospina NM, et al. Clinical outcomes after discontinuation of thyroid hormone replacement: a systematic review and meta-analysis. *Thyroid*. 2021;31(5):740-751. doi:10.1089/thy.2020.0679